Participation of cycooxygenase‐2‐derived products in the development of hypertension in the SHR

Abstract

Several studies have suggested cyclooxygenase‐2 (COX‐2) plays a significant role in the development of renovascular hypertension. Therefore, the present study was designed to examine the effect of celecoxib a selective COX‐2 inhibitor on the development of hypertension in SHR. Four‐weeks‐old male SHR were divided into four groups: a) Control, b) Celecoxib 0.5 mg/kg/day, c) Celecoxib 1 mg/kg/day, and d) Captopril 30 mg/kg/day. SHR were treated by 10 weeks with these inhibitors in the drinking water. Body weight, heart rate (FC) and systolic blood pressure were evaluated. Kidneys were mounted into an isolated organ chamber in order to measure the contractile response to phenylephrine (alpha‐1 adrenoceptor agonist). At the end of the captopril and celecoxib treatment, systolic blood pressure was reduced in SHR treated (control: 169.7 ± 5.12 mm Hg, celecoxib 0.5 mg/kg: 147.9 ± 5.21 mm Hg, celecoxib 1 mg/kg: 138.7 ± 4.91 mm Hg and captopril 117. 22 ± 3.73). The body weight and heart rate were not modified by treatments. The vasoconstrictor renal response to phenylephrine was lower in SHR than WKY rats. Captopril and celecoxib treatments normalized the contractile response to phenylephrine. These results suggest cyclooxigenase‐2‐derived metabolites could be involved in the development of hypertension in the SHR.Supported by PAPIIT IN218406